Moreno, Lucas, Caron, Hubert, Geoerger, Birgit, Eggert, Angelika, Schleiermacher, Gudrun, Brock, Penelope, Valteau-Couanet, Dominique, Chesler, Louis, Schulte, Johannes H, De Preter, Katleen, and others. (2017) Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 12 (8). pp. 801-811. ISSN 1746-0441. E-ISSN 1746-045X. (doi:10.1080/17460441.2017.1340269) (KAR id:63861)
|
PDF
Author's Accepted Manuscript
Language: English |
|
|
Download (325kB)
Preview
|
Preview |
|
This file may not be suitable for users of assistive technology.
Request an accessible format
|
|
|
PDF (Abbreviations)
Supplemental Material
Language: English |
|
|
Download (185kB)
Preview
|
Preview |
|
This file may not be suitable for users of assistive technology.
Request an accessible format
|
|
|
PDF (Table 1)
Supplemental Material
Language: English |
|
|
Download (375kB)
Preview
|
Preview |
|
This file may not be suitable for users of assistive technology.
Request an accessible format
|
|
|
PDF (Table 2)
Supplemental Material
Language: English |
|
|
Download (243kB)
Preview
|
Preview |
|
This file may not be suitable for users of assistive technology.
Request an accessible format
|
|
|
PDF (Table 3)
Supplemental Material
Language: English |
|
|
Download (285kB)
Preview
|
Preview |
|
This file may not be suitable for users of assistive technology.
Request an accessible format
|
|
| Official URL http://dx.doi.org/10.1080/17460441.2017.1340269 |
|
Abstract
Introduction: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients.
Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1080/17460441.2017.1340269 |
| Uncontrolled keywords: | Neuroblastoma, drug development, phase I, preclinical testing, clinical trials |
| Subjects: | Q Science |
| Divisions: | Divisions > Division of Natural Sciences > School of Biosciences |
| Depositing User: | Michelle Garrett |
| Date Deposited: | 06 Oct 2017 08:31 UTC |
| Last Modified: | 13 Mar 2020 04:09 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/63861 (The current URI for this page, for reference purposes) |
| Garrett, Michelle D.: |  https://orcid.org/0000-0002-3939-1673 |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
